News
BFRIW
--
0.00%
--
Biofrontera Inc. Announces Closing of $9.4 Million Private Placement
WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the closing of its previously-announced $9.4 million private plac...
GlobeNewswire · 2d ago
BRIEF-Biofrontera Inc Announces Pricing Of $9.4 Million Private Placement
reuters.com · 5d ago
Biofrontera Inc. Announces Pricing of $9.4 Million Private Placement
WOBURN, MA., May 16, 2022 (GLOBE NEWSWIRE) -- Biofrontera, Inc. (Nasdaq: BFRI; BFRIW), announced today that it has entered into a securities purchase agreement with a single institutional investor for the purchase of 3,419,000 shares of its common stock (o...
GlobeNewswire · 5d ago
BRIEF-Biofrontera Reports Q1 Revenue Rose 106%
reuters.com · 05/13 11:35
Biofrontera Inc. to Report First Quarter Financial Results on May 13, 2022
WOBURN, Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, will report financial results for the three months ended March 31, 2022 before th...
GlobeNewswire · 05/06 12:25
Biofrontera Inc. to Showcase Actinic Keratosis Treatments at the Music City Symposium for Cosmetic Advances & Laser Education
Live Demonstration of New RhodoLED® XL to be Featured WOBURN, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today its sponsor...
GlobeNewswire · 05/05 12:30
Biofrontera Launches New Patient-Focused Websites for Ameluz® and Xepi®
Ameluz® for the treatment of actinic keratoses now at www.ameluz.comXepi® for the treatment of impetigo now at www.xepicream.com WOBURN, Mass. , April 21, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in...
GlobeNewswire · 04/21 17:20
Biofrontera Inc. Announces FDA Approval of Biofrontera Pharma GmbH as a Contract Laboratory for Ameluz®
Significantly Improves Manufacturing Efficiency, Quality Control and Supply Reliability WOBURN, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological p...
GlobeNewswire · 04/13 14:10
Biofrontera Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update
Introduces 2022 financial guidanceConference call begins at 11:00 a.m. Eastern time today WOBURN, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization o...
GlobeNewswire · 04/08 11:42
Biofrontera Inc. Announces Preliminary Product Revenues for the First Quarter of 2022
WOBURN, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today preliminary, unaudited product revenues for the quarter ended M...
GlobeNewswire · 04/06 12:30
Biofrontera Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on April 8, 2022
WOBURN, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today it will report financial results for the three months and full ...
GlobeNewswire · 04/01 17:00
Biofrontera to Showcase Actinic Keratoses and Impetigo Treatments at the 2022 American Academy of Dermatology Annual Meeting
Company to have a strong onsite presence at the world’s largest scientific conference for dermatologists, with approximately 10,000 medical professionals expected to attend WOBURN, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), ...
GlobeNewswire · 03/17 15:20
Biofrontera Inc. to Present at the 34th Annual Roth Conference
WOBURN, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, announces today that Erica Monaco, Chief Executive Officer, wil...
GlobeNewswire · 03/09 16:08
BRIEF-Biofrontera Appoints Kevin D. Weber To Its Board Of Directors
reuters.com · 03/07 13:52
Biofrontera Inc. Appoints Kevin D. Weber to its Board of Directors
WOBURN, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, announces the appointment of Kevin D. Weber to its Board of Dir...
GlobeNewswire · 03/07 13:50
Biofrontera Inc. provides Update on Patient Recruitment for Phase III Study for the Treatment of sBCC with Ameluz®-PDT
WOBURN, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, is pleased to provide an update on the patient recruitment for t...
GlobeNewswire · 02/01 13:47
Biofrontera Inc. Issues Letter to Shareholders Highlighting 2021 Successes and Key Elements of the Strategic Plan for 2022 and Beyond
WOBURN, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today issued the following letter from CEO Erica Monaco and Exec...
GlobeNewswire · 01/18 14:25
Biofrontera Inc. Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021
WOBURN, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced preliminary, unaudited revenue for the quarter a...
GlobeNewswire · 01/13 13:45
Biofrontera Inc. Announces Participation in Two Dermatology Conferences in January
WOBURN, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that it plans to participate in the following tw...
GlobeNewswire · 01/10 13:45
Biofrontera Inc. announces reduction of Biofrontera AG shareholding to less than 50% through warrant exercises
WOBURN, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced that through the exercise of outstanding warrants the majority ownersh...
GlobeNewswire · 12/30/2021 13:45
Webull provides a variety of real-time BFRIW stock news. You can receive the latest news about Biofrontera through multiple platforms. This information may help you make smarter investment decisions.
About BFRIW
Biofrontera Inc. is a biopharmaceutical company. The Company is specialized in the commercialization of pharmaceutical products for the treatment of dermatological conditions for the diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its products focus on the treatment of actinic keratoses, which are skin lesions that lead to skin cancer. It also markets a topical antibiotic for treatment of impetigo, a bacterial skin infection. The Company’s principal product is Ameluz, which is a prescription drug for use in combination with its medical device, the BF-RhodoLED lamp, for photodynamic therapy (PDT) in the United States for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It offers Xepi for the treatment of impetigo, a common skin infection, due to Staphylococcus aureus or streptococcus pyogenes.